Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Tetsuya Oguri"'
Autor:
Osamu Takakuwa, Akira Takeuchi, Kensuke Fukumitsu, Tomoko Tajiri, Kazuki Sone, Yusuke Kagawa, Tetsuya Oguri, Yutaka Ito, Takehiro Uemura, Yoshihiro Kanemitsu, Masaya Takemura, Satoshi Fukuda, Akio Niimi, Ken Maeno, Hirotsugu Ohkubo
Publikováno v:
Anticancer Research. 40:4245-4251
Background Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives. SLC22A16 has functional genetic variants but the associatio
Autor:
Ayako Masaki, Akio Niimi, Osamu Takakuwa, Eiji Kunii, Tetsuya Oguri, Masaya Takemura, Kensuke Fukumitsu, Yusuke Kagawa, Takehiro Uemura, Satoshi Fukuda, Kazuki Sone, Hiroshi Inagaki, Hirotsugu Ohkubo, Yutaka Ito, Akira Takeuchi, Ken Maeno, Yoshihiro Kanemitsu
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Objectives: Small cell lung cancer (SCLC) is an aggressive and highly metastatic lung cancer subtype. Nestin is a member of the intermediate filament family and serves as a potential proliferative and multipotency marker in neural progenitor and stem
Autor:
Tetsuya Oguri, Yutaka Ito, Tomoko Tajiri, Norihisa Takeda, Hirotsugu Ohkubo, Ken Maeno, Akio Niimi, Satoshi Fukuda, Kensuke Fukumitsu, Masaya Takemura, Yoshihiro Kanemitsu, Keima Ito
Publikováno v:
Respiratory Medicine Case Reports
Respiratory Medicine Case Reports, Vol 29, Iss, Pp-(2020)
Respiratory Medicine Case Reports, Vol 29, Iss, Pp-(2020)
A 76-year-old man was admitted to our hospital with cough and dyspnea. He was diagnosed with advanced lung cancer. Nivolumab was given as second-line treatment, cytotoxic chemotherapy was given as third-line treatment, and nivolumab re-challenge was
Autor:
Masaya Takemura, Yoshitsugu Inoue, Akira Takeuchi, Akio Niimi, Osamu Takakuwa, Yutaka Ito, Yoriko Yamashita, Kensuke Fukumitsu, Tetsuya Oguri, Satoshi Fukuda, Sayaka Yamamoto, Kazuki Sone, Takehiro Uemura, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Ken Maeno, Hirono Nishiyama, Tomoko Tajiri
Publikováno v:
Mol Clin Oncol
Docetaxel is one of the standard second/third-line treatments for non-small-cell lung cancer (NSCLC) following a failed response to prior cytotoxic chemotherapy. The predictive biomarker for the effectiveness of docetaxel therapy remains undetermined
Autor:
Takashi Kijima, Hidetoshi Hayashi, Kazuhiko Nakagawa, Yoichi Nakanishi, Takashi Niwa, Tetsuya Oguri, Yoshihito Kogure, Katsuya Watanabe, Seiji Yano, Akira Ono, Naruo Yoshimura, Kazuhisa Asai, Yasutaka Chiba, Tomoya Kawaguchi, Tatsuo Kimura, Takashi Kasai, Nobuyuki Yamamoto, Hiroshi Tanaka, Hiroshige Yoshioka
Publikováno v:
Japanese journal of clinical oncology. 49(10)
Background Preclinical data suggest sequential administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) following chemotherapy may improve efficacy. We hypothesized that intermittent delivery of EGFR-TKI following che
Autor:
Takeharu Yamanaka, Takashi Seto, Takashi Nishimura, Haruko Daga, Takehito Shukuya, Yoichi Nakanishi, Hideo Saka, Koichi Goto, Seisuke Nagase, Tetsuya Oguri, Soichiro Yokota, Kazuhiko Nakagawa, Yoshihiro Hattori, Toshiaki Takahashi, Yasuo Iwamoto, Nobuyuki Yamamoto, Shunichi Sugawara, Tomoya Kawaguchi, Hiroyasu Kaneda
Publikováno v:
The Lancet Oncology. 16:1630-1638
Summary Background The combination of nedaplatin, a cisplatin derivative, and docetaxel showed promising activity for advanced squamous cell lung carcinoma in a previous phase 1–2 study. We compared nedaplatin plus docetaxel with cisplatin plus doc
Autor:
Tomohiko Ogasawara, Takashi Abe, Tomoki Kimura, Yoshitsugu Horio, Tetsunari Hase, Yasuteru Sugino, Hiroshi Saito, Yoshinori Hasegawa, Kazuyoshi Imaizumi, Eiji Kojima, Tetsuya Oguri, Masahiro Nakatochi, Hideo Saka, Masahiko Ando, Kiyoshi Yanagisawa, Masashi Kondo, Asuki Fukatsu, Masashi Yamamoto, Masahiro Morise, Takashi Takahashi
Publikováno v:
Journal of Clinical Oncology. 38:9524-9524
9524 Background: At present, platinum-doublet chemotherapy or in combination with an immune check point inhibitor are standard treatment for patients with metastatic or recurrent NSCLC which lacks somatic gene alterations. Although CbP is one of the
Autor:
Masaya Takemura, Yutaka Ito, Yoshihiro Kanemitsu, Takehiro Uemura, Hirotsugu Ohkubo, Ken Maeno, Satoshi Fukuda, Takamitsu Asano, Akio Niimi, Tetsuya Oguri, Osamu Takakuwa
Publikováno v:
Respiratory investigation. 56(5)
Background Hypoxemia during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is often encountered even in patients without respiratory impairment before the procedure. The aim of this study was to evaluate the efficacy of
Autor:
Hideki Muramatsu, Hirotsugu Ohkubo, Satoshi Fukuda, Akio Niimi, Makoto Nakao, Takehiro Uemura, Ken Maeno, Yutaka Ito, Yoshihiro Kanemitsu, Ryota Kurowaka, Kazuki Sone, Osamu Takakuwa, Yusuke Kagawa, Tetsuya Oguri, Masaya Takemura, Hiromi Furuta, Hidefumi Sato
Publikováno v:
Anticancer research. 37(2)
BACKGROUND Pretreatment serum tumor marker levels predict outcome in non-small cell lung cancer (NSCLC). However, little is known about the clinical value of such measurements for patients treated with pemetrexed plus a platinum-derivative. PATIENTS
Autor:
Tetsuya Oguri, Osamu Takakuwa, Takamitsu Asano, Hisatoshi Hijikata, Hiroya Ichikawa, Yutaka Ito, Atsushi Nakamura, Ken Maeno, Takehiro Uemura, Akio Niiimi, Masaya Takemura, Kensuke Fukumitsu, Hirotsugu Ohkubo, Norihisa Takeda
Publikováno v:
5.3 Allergy and Immunology.
Background: Small airways are likely involved in asthma, but whether small airways disease play relevant roles in specific asthma phenotypes is unknown. Only a few studies addressed AHR of small airways by using IOS in adult asthma. Purpose: To inves